Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

64.800
+0.1000.15%
Volume:558.92K
Turnover:35.48M
Market Cap:35.22B
PE:38.91
High:64.900
Open:64.900
Low:62.050
Close:64.700
52wk High:92.000
52wk Low:15.200
Shares:543.49M
HK Float Shares:163.43M
Volume Ratio:0.90
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.665
ROE:27.54%
ROA:4.97%
PB:9.37
PE(LYR):38.91
PS:5.51

Loading ...

Organon, Shanghai Henlius Say EU Approves Denosumab Biosimilars

MT Newswires Live
·
Sep 19

HENLIUS (02696): European Commission Approves HLX14 (Denosumab) Products for Osteoporosis Treatment in Specific Patient Populations

Stock News
·
Sep 19

European Commission (Ec) Approves Henlius and Organon’s Bildyos® (Denosumab) and Bilprevda® (Denosumab), Biosimilars to Prolia (Denosumab) and Xgeva (Denosumab), Respectively

THOMSON REUTERS
·
Sep 19

Shanghai Henlius Biotech Inc - Bilprevda® Approved for Skeletal Event Prevention

THOMSON REUTERS
·
Sep 19

Shanghai Henlius Biotech Inc - Ec Approves Hlx14 Products for Osteoporosis Treatment

THOMSON REUTERS
·
Sep 19

Henlius Biotech Doses First Patient in Lung Cancer Drug Trial in Australia

MT Newswires Live
·
Sep 18

HENLIUS (02696): First Patient Dosed in Australia for International Multi-center Phase 2 Clinical Study of HLX43 (PD-L1 Targeted Antibody-Drug Conjugate) for Advanced Non-Small Cell Lung Cancer Treatment

Stock News
·
Sep 18

China Merchants Securities Maintains "Strong Recommendation" Rating on HENLIUS (02696), Optimistic About HLX43's Drug Development Potential

Stock News
·
Sep 18

HENLIUS (02696) Maintains "Buy" Rating with Target Price Raised to HK$120.87

Stock News
·
Sep 16

Hong Kong Stocks Alert | HENLIUS (02696) Surges Over 9% Intraday Amid Reports of HLX43 Licensing Negotiations with Johnson & Johnson and Roche

Stock News
·
Sep 16

Market Chatter: Henlius Biotech in Talks With J&J, Roche on Cancer Drug Rights; Shares Up 3%

MT Newswires Live
·
Sep 16

Can Henlius Keep Its Momentum After Announcing New FDA Approval in 2025?

Simply Wall St.
·
Sep 14

Core Innovation Pipeline Continues to Drive Growth: Morgan Stanley Assigns 72 Billion Yuan Valuation to HENLIUS (02696), Target Price Reaches New High

Stock News
·
Sep 10

Henlius Biotech's Gets US FDA Nod for Trial of Tumor Drug

MT Newswires Live
·
Sep 08

BRIEF-Shanghai Henlius Biotech SAys FDA Approves IND Application For Henlius' Biosimilar Hlx17

Reuters
·
Sep 08

Fosun Pharma's (600196.SH) Subsidiary Henlius Receives US FDA Approval for HLX17 Clinical Trial

Stock News
·
Sep 08

HENLIUS (02696): FDA Approves Clinical Trial Application for Pembrolizumab Biosimilar HLX17 in Patients with Multiple Resected Solid Tumors

Stock News
·
Sep 08

Shanghai Henlius Biotech Inc - FDA Approves Ind Application for Henlius' Biosimilar Hlx17

THOMSON REUTERS
·
Sep 08

Hong Kong Stock Alert | HENLIUS (02696) Surges Over 8% in Early Trading, Stock Price Hits New Historical High as Vorvicimib Receives First Prescriptions Nationwide

Stock News
·
Sep 08

Hong Kong Stock Movement | HENLIUS (02696) Surges Nearly 5% in Early Trading Following Point72 Hedge Fund Stake Increase and Breakthrough Growth in Overseas Product Profits

Stock News
·
Sep 05